Probenecid
- Generic Name
- Probenecid
- Drug Type
- Small Molecule
- Chemical Formula
- C13H19NO4S
- CAS Number
- 57-66-9
- Unique Ingredient Identifier
- PO572Z7917
- Background
The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
- Indication
For the reduction of serum uric acid concentrations in chronic gouty arthritis and tophaceous gout in patients with frequent disabling gout attacks. Has also been effectively used to promote uric acid excretion in hyperuricemia secondary to the administration of thiazide and related diuretics.
- Associated Conditions
- Bacterial Infections, Chronic Gouty Arthritis, Elevated Serum Uric Acid, Gout Chronic, Hyperuricemia, Infection
Assessment of a New "Boosting" Strategy for HIV Pre-exposure Prophylaxis in Healthy Volunteers
- Conditions
- Pre-Exposure Prophylaxis
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-05-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 15
- Registration Number
- NCT03202511
- Locations
- 🇺🇸
Indiana University Clinical Research Center at University Hospital, Indianapolis, Indiana, United States
Effect of Probenecid on Pexidartinib Pharmacokinetics
- Conditions
- Pharmacokinetics in Healthy Volunteers
- Interventions
- First Posted Date
- 2017-05-03
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 16
- Registration Number
- NCT03138759
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, San Antonio, Texas, United States
A Phase 1 Study to Evaluate the Effect of the Organic Anion Transporter Inhibitor Probenecid on the Pharmacokinetics of JNJ-64041575 in Healthy Adults
- First Posted Date
- 2017-04-10
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 18
- Registration Number
- NCT03105986
- Locations
- 🇩🇪
Charité Research Organisation GmbH, Berlin, Germany
Effect of Probenecid on Synovial Fluid ATP Levels in CPPD
- Conditions
- Calcium Pyrophosphate Deposition Disease
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 8
- Registration Number
- NCT02243631
- Locations
- 🇺🇸
Clement J. Zablocki VA Medical Center, Milwaukee, WI, Milwaukee, Wisconsin, United States
A Study of Baricitinib and Probenecid in Healthy Participants
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2017-06-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 18
- Registration Number
- NCT01937026
- Locations
- 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom
Intravesical Cidofovir for Hemorrhagic Cystitis
- Conditions
- Blood And Marrow Transplantation
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01816646
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure
- Conditions
- Systolic Heart Failure
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 20
- Registration Number
- NCT01814319
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
Drug-interaction Trial in Healthy Subjects With Oral Administration of Empagliflozin (BI 10773), Rifampicin and Probenecid
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-07-06
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT01634100
- Locations
- 🇩🇪
1245.83.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury
- Conditions
- Pediatric Traumatic Brain Injury
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-03-24
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 14
- Registration Number
- NCT01322009
- Locations
- 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function
- Conditions
- Renal FunctionOverweightObesityEndothelial FunctionBlood Pressure
- Interventions
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2017-06-29
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 242
- Registration Number
- NCT01320722
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.